Gorelick, Alexander N. http://orcid.org/0000-0001-6736-8246
Kim, Minsoo
Chatila, Walid K.
La, Konnor
Hakimi, A. Ari http://orcid.org/0000-0002-0930-8824
Berger, Michael F.
Taylor, Barry S.
Gammage, Payam A. http://orcid.org/0000-0003-1968-1726
Reznik, Ed http://orcid.org/0000-0002-6511-5947
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, F31 7F31CA247528-02, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM132083, U54 OD020355, R01 CA207244, R01 CA204749, R01 CA245069)
American Cancer Society
Cancer Research UK (A17196, A31287)
Geoffrey Beene Cancer Research Center
Article History
Received: 9 September 2020
Accepted: 3 March 2021
First Online: 8 April 2021
Competing interests
: B.S.T. reports receiving honoria and research funding from Genentech and Illumina, and advisory board activities for Boehringer Ingelheim and Loxo Oncology, a wholly owned subsidiary of Eli Lilly, Inc. All stated activities were outside the work described in the present study. He is currently an employee of Loxo Oncology. P.A.G. is a shareholder of Pretzel Therapeutics Inc. The remaining authors declare no competing interests.